Fig. 3 | Leukemia

Fig. 3

From: Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

Fig. 3

Overall survival and event-free survival. Overall survival of all patients (a), of patients younger than <60 years (b), of patients older than ≥60 years (c). Event-free survival of all patients (d), of patients younger than <60 years (e), of patients older than ≥60 years (f)—always biological age as defined in “Patients and methods”